Name | Number of supported studies | Average coverage | |
---|---|---|---|
classical monocyte | 25 studies | 56% ± 17% | |
non-classical monocyte | 23 studies | 65% ± 17% | |
conventional dendritic cell | 22 studies | 46% ± 22% | |
dendritic cell | 19 studies | 41% ± 20% | |
monocyte | 18 studies | 44% ± 18% | |
macrophage | 7 studies | 36% ± 18% | |
neutrophil | 6 studies | 50% ± 18% | |
monocyte-derived dendritic cell | 4 studies | 42% ± 23% | |
mononuclear phagocyte | 4 studies | 43% ± 14% | |
myeloid cell | 4 studies | 35% ± 10% | |
intermediate monocyte | 4 studies | 73% ± 9% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 12 studies | 22% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 100% | 924.20 | 578 / 578 | 2% | 0.03 | 21 / 1155 |
liver | 99% | 471.91 | 224 / 226 | 1% | 0.01 | 4 / 406 |
spleen | 100% | 5862.21 | 241 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 11932.21 | 916 / 929 | 0% | 0 | 0 / 0 |
adipose | 98% | 476.45 | 1184 / 1204 | 0% | 0 | 0 / 0 |
adrenal gland | 96% | 187.90 | 248 / 258 | 0% | 0.01 | 1 / 230 |
breast | 89% | 210.54 | 410 / 459 | 0% | 0.00 | 3 / 1118 |
intestine | 87% | 231.77 | 837 / 966 | 0% | 0.00 | 2 / 527 |
bladder | 86% | 171.52 | 18 / 21 | 1% | 0.02 | 5 / 504 |
brain | 77% | 136.42 | 2024 / 2642 | 2% | 0.03 | 13 / 705 |
thymus | 69% | 102.05 | 448 / 653 | 6% | 0.11 | 34 / 605 |
esophagus | 68% | 138.61 | 984 / 1445 | 0% | 0 | 0 / 183 |
heart | 65% | 131.74 | 558 / 861 | 0% | 0 | 0 / 0 |
skin | 61% | 102.44 | 1107 / 1809 | 2% | 0.04 | 10 / 472 |
ovary | 60% | 91.77 | 108 / 180 | 1% | 0.01 | 3 / 430 |
prostate | 60% | 79.84 | 147 / 245 | 0% | 0 | 0 / 502 |
blood vessel | 56% | 110.57 | 743 / 1335 | 0% | 0 | 0 / 0 |
stomach | 53% | 118.01 | 190 / 359 | 1% | 0.02 | 2 / 286 |
uterus | 46% | 75.18 | 79 / 170 | 1% | 0.02 | 3 / 459 |
kidney | 45% | 80.28 | 40 / 89 | 1% | 0.02 | 12 / 901 |
lymph node | 0% | 0 | 0 / 0 | 45% | 1.03 | 13 / 29 |
pancreas | 12% | 14.87 | 39 / 328 | 4% | 0.05 | 8 / 178 |
muscle | 11% | 12.13 | 85 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006955 | Biological process | immune response |
GO_0050778 | Biological process | positive regulation of immune response |
GO_0006957 | Biological process | complement activation, alternative pathway |
GO_0006956 | Biological process | complement activation |
GO_0042742 | Biological process | defense response to bacterium |
GO_1903028 | Biological process | positive regulation of opsonization |
GO_0005615 | Cellular component | extracellular space |
GO_0005788 | Cellular component | endoplasmic reticulum lumen |
GO_1904724 | Cellular component | tertiary granule lumen |
GO_0005576 | Cellular component | extracellular region |
GO_0062023 | Cellular component | collagen-containing extracellular matrix |
GO_0035580 | Cellular component | specific granule lumen |
GO_0098548 | Cellular component | cytoplasmic side of Golgi membrane |
GO_0005515 | Molecular function | protein binding |
Gene name | CFP |
Protein name | Complement factor properdin isoform 2 Properdin (Complement factor P) Complement factor properdin, isoform CRA_c (cDNA FLJ16673 fis, clone THYMU3003403, highly similar to Properdin) Alternative protein CFP Complement factor properdin isoform 1 (Complement factor properdin, isoform CRA_d) Complement factor properdin |
Synonyms | PFC hCG_29138 |
Description | FUNCTION: A positive regulator of the alternate pathway (AP) of complement . It binds to and stabilizes the C3- and C5-convertase enzyme complexes . Inhibits CFI-CFH mediated degradation of Complement C3 beta chain (C3b) . . |
Accessions | A0A0S2Z515 ENST00000247153.7 L0R836 ENST00000469388.1 E9PAQ1 B3KVK6 ENST00000377005.6 ENST00000396992.8 P27918 C9J7V5 A0A0S2Z4I5 |